Vigil Neuroscience develops microglia-targeted therapeutics that activate TREM2, a receptor crucial for maintaining brain homeostasis, to address neurodegenerative diseases linked to microglial dysfunction. By employing a precision medicine approach, the company aims to create targeted drug candidates for genetically defined patient subpopulations, ultimately expanding to broader patient populations.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Neurodegenerative diseases are often linked to dysfunctional microglia, the brain's immune cells responsible for maintaining homeostasis. Current treatments do not adequately address the underlying microglial dysfunction, leaving a significant unmet need for targeted therapies. This is especially true for genetically defined patient subpopulations where microglial dysfunction plays a key role.
Solution
Vigil Neuroscience is developing microglia-targeted therapeutics designed to restore microglial vigilance and treat both rare and common neurodegenerative diseases. Their approach focuses on activating TREM2, a receptor crucial for microglial function, using precision medicine to target genetically defined patient subpopulations. By selectively activating TREM2, the company aims to restore brain homeostasis and improve outcomes for patients suffering from neurodegenerative conditions. The company ultimately intends to expand therapeutic applications to larger patient populations, leveraging insights gained from initial precision-based programs.
Target Audience
The primary target audience includes patients with rare and common neurodegenerative diseases, their caregivers, and patient advocacy groups, particularly those with genetically defined conditions linked to microglial dysfunction.
Features
- Highly selective TREM2 activators designed to enhance microglial function.
- Precision medicine approach targeting genetically defined patient subpopulations.
- Focus on restoring brain homeostasis by addressing microglial dysfunction.
- Development of novel drug candidates for neurodegenerative diseases.